A predictive tool for an effective use of 18F-FDG PET in assessing activity of sarcoidosis

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Mostard, Rémy L M ^a   Kuijk, Sander M J Van ^b   Verschakelen, Johny A ^c   Kroonenburgh, Marinus J P G van ^d   Nelemans, Patty J ^b   Wijnen, Petal A H M ^d   Drent, Marjolein ^b,e,f  

^a Sittard Geleen Heerlen   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Department of interstitial lung diseases   (Netherlands)

^f NONE   (Netherlands)

Author keywords

Clinical prediction rule; High resolution computed tomography; PET; Sarcoidosis; Soluble interleukin 2 receptor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; QUALITY OF LIFE; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 84866160179     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-57     Document Type: Article

References (37)

1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16:149-73.
2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. Jama 2011, 305:391-9. 10.1001/jama.2011.10, 21266686.
3. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008, 25:76-89.
4. Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994, 7:624-7.
5. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18 F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008, 25:143-9.
6. Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003, 21:407-13. 10.1183/09031936.03.00010403, 12661993.
7. Keijsers RG, Verzijlbergen FJ, Oyen WJ, van den Bosch JM, Ruven HJ, van Velzen-Blad H, Grutters JC. 18 F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009, 36:1131-7. 10.1007/s00259-009-1097-x, 19259660.
8. Mostard RLM, Voo S, van Kroonenburgh MJPG, Verschakelen JA, Wijnen PAHM, Nelemans PJ, Erckens RJ, Drent M. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011, 105:1917-1924. 10.1016/j.rmed.2011.08.012, 21899998.
9. Vardhanabhuti V, Venkatanarasimha N, Bhatnagar G, Maviki M, Iyengar S, Adams WM, Suresh P. Extra-pulmonary manifestations of sarcoidosis. Clin Radiol 2012, 67:263-76. 10.1016/j.crad.2011.04.018, 22094184.
10. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011, 183:573-81. 10.1164/rccm.201006-0865CI, 3081278, 21037016.
11. Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010, 31:501-18. 10.1055/s-0030-1262218, 20665400.
12. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:127-36.
13. Marcellis RG, Lenssen AF, Elfferich MD, De Vries J, Kassim S, Foerster K, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011, 38:628-34. 10.1183/09031936.00117710, 21436356.
14. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012, 8:95-103. 10.1586/eci.11.84, 22149344.
15. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004, 34:313-29. 10.1053/j.semnuclmed.2004.06.006, 15493008.
16. Basu S, Saboury B, Werner T, Alavi A. Clinical Utility of FDG-PET and PET/CT in Non-malignant Thoracic Disorders. Mol Imaging Biol 2010, 13:1051-60.
17. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007, 132:1949-53. 10.1378/chest.07-1178, 17925421.
18. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18 F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008, 35:1537-43. 10.1007/s00259-008-0770-9, 18418595.
19. Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, Ohkawa M. Comparative evaluation of 18 F-FDG PET and 67 Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006, 47:1571-6.
20. Keijsers RG, Grutters JC, Thomeer M, Du Bois RM, Van Buul MM, Lavalaye J, Van Den Bosch JM, Verzijlbergen FJ. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging 2011, 55:66-71.
21. Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18 F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:87-94.
22. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, Gulenchyn KY, Dekemp RA, Dasilva J, Birnie D, et al. The use of 18 F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012, 53:241-8. 10.2967/jnumed.111.090662, 22228794.
23. Mostard RL, Verschakelen JA, van MJPG K, Voo S, Wijnen PAHM DM. Association of HRCT findings with pulmonary PET activity in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:13.
24. Keijsers RG, Verzijlbergen FJ, van den Bosch JM, Zanen P, van de Garde EM, Oyen WJ, G J C. 18F-FDG PET as predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:123-129.
25. de Kleijn WP, Elfferich MD, De Vries J, Jonker GJ, Lower EE, Baughman RP, King TE, Drent M. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26:92-7.
26. Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med 2011, 105:95-100. 10.1016/j.rmed.2010.09.014, 20889323.
27. Oberstein A, von Zitzewitz H, Schweden F, Muller-Quernheim J. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis 1997, 14:65-72.
28. Drent M, De Vries J, Lenters M, Lamers RJ, Rothkranz-Kos S, Wouters EF, van Dieijen-Visser MP, Verschakelen JA. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003, 13:2462-2471. 10.1007/s00330-003-1965-x, 12811502.
29. Frank J, Harrell E. Regression Modeling Strategies 2001, Springer, New York.
30. Allison PD. Missing Data 2001, Sage, Iowa.
31. Steyerberg EW. Clinical Prediction Models 2009, Springer, New York.
32. Rubin DB. Inference and missing data. Biometrika 1976, 63:581-592.
33. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
34. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010, 21:128-38. 10.1097/EDE.0b013e3181c30fb2, 20010215.
35. Mostard R, Prompers L, Weijers R, van Kroonenburgh M, Wijnen P, Geusens P, Drent M. F18 FDG-PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med 2012, 37:21-5. 10.1097/RLU.0b013e3182335f9b, 22157023.
36. Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNFalpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2011, [Epub ahead of print].
37. Teirstein AT, Morgenthau AS. "End-stage" pulmonary fibrosis in sarcoidosis. Mt Sinai J Med 2009, 76:30-6. 10.1002/msj.20090, 19170216.